About The Study: Fecal microbiota transplantation (FMT) was safe but did not offer clinically meaningful improvements. Further studies—for example, through modified FMT approaches or bowel cleansing—are warranted regarding the specific impact of donor microbiota composition and dysbiosis conversion on motor and nonmotor outcomes as well as medication needs in Parkinson disease.
About The Study: Fecal microbiota transplantation (FMT) was safe but did not offer clinically meaningful improvements. Further studies—for example, through modified FMT approaches or bowel cleansing—are warranted regarding the specific impact of donor microbiota composition and dysbiosis conversion on motor and nonmotor outcomes as well as medication needs in Parkinson disease.
Corresponding Author: To contact the corresponding author, Filip Scheperjans, M.D., Ph.D., email filip.scheperjans@hus.fi.
To access the embargoed study: Visit our For The Media website at this link
(doi:10.1001/jamaneurol.2024.2305)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time
Journal
JAMA Neurology
Cite Scienmag News
Cassandra Pierce. (July 29, 2024). Fecal microbiota transplantation for treatment of Parkinson disease. Scienmag. https://scienmag.com/fecal-microbiota-transplantation-for-treatment-of-parkinson-disease/
Cassandra Pierce. "Fecal microbiota transplantation for treatment of Parkinson disease." Scienmag, 29 July 2024, https://scienmag.com/fecal-microbiota-transplantation-for-treatment-of-parkinson-disease/. Accessed 5 September 2026.
Cassandra Pierce. "Fecal microbiota transplantation for treatment of Parkinson disease." Scienmag. July 29, 2024. https://scienmag.com/fecal-microbiota-transplantation-for-treatment-of-parkinson-disease/
